MANA 412
Alternative Names: MANA-412Latest Information Update: 14 May 2021
Price :
$50 *
At a glance
- Originator Mana Therapeutics
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Solid tumours
Most Recent Events
- 10 May 2021 Mana Therapeutics plans to file an IND application with the US FDA for Acute myeloid leukaemia and Solid tumours by early 2022
- 25 Mar 2021 MANA 412 is available for licensing as of 25 Mar 2021 https://www.manatherapeutics.com/collaborations
- 25 Mar 2021 Preclinical trials in Acute myeloid leukaemia in USA (Parenteral) (Mana Therapeutics pipeline, March 2021)